Seroprevalence of hepatitis B and associated factors among inmates: a cross sectional study in the Douala New Bell Prison, Cameroon.
Cameroon
Prevalence
hepatitis B
prison
risks factors
Journal
The Pan African medical journal
ISSN: 1937-8688
Titre abrégé: Pan Afr Med J
Pays: Uganda
ID NLM: 101517926
Informations de publication
Date de publication:
2021
2021
Historique:
received:
17
09
2019
accepted:
08
05
2020
entrez:
9
8
2021
pubmed:
10
8
2021
medline:
26
8
2021
Statut:
epublish
Résumé
in Cameroon, data on viral hepatitis B infection in prison environments is limited. We determined the prevalence of hepatitis B infection (HBV) and correlates among prisoners incarcerated at the Douala New Bell Central Prison in Cameroon. this was a cross-sectional study carried out in July 2018 and included 940 randomly selected prisoners. Data were collected using pre-tested questionnaire while blood screening for HBV surface antigen (HBs Ag) used rapid test, with confirmation via Elisa test. Sociodemographic characteristics and risk factors were compared among the three age groups with respect to the prison's partitioning. Factors associated with positive HBs Ag were identified using logistic regression adjusted to age and gender. Confounders were then excluded by logistic multivariate analysis. All p values less than 0.05 were considered statistically significant. of the 940 prisoners selected, 94% were male. The mean age of the study population was 33.81 ± 10.35 years. The median duration of incarceration and median number of incarcerations were 12 months (IQR: 5-36) and 1 (IQR: 1-2) respectively. HBV prevalence was 12.9% (95% CI: 10.7-15%). The use of non-injectable illicit drugs (OR: 3.5; 95% CI: 1.9-6.2; P<0.001), sharing of needle or razors (aOR: 24.1; 95% CI: 12.9-45.0; P<0.001), sharing of tooth brushes(aOR: 2.7; 95% CI: 0.9-7.4) (P=0.053), having tattoos or piercings (aOR: 1.9; 95% CI: 1.1-3.1; P=0.01) were significantly associated with HBs Ag seropositivity. prisoners in this setting had a high prevalence of HBV and related risk factors. These findings highlight an urgent need to implement control strategies and programs that reach people in detention centers in Cameroon.
Identifiants
pubmed: 34367434
doi: 10.11604/pamj.2021.38.355.20386
pii: PAMJ-38-355
pmc: PMC8309011
doi:
Substances chimiques
Hepatitis B Surface Antigens
0
Hepatitis C Antibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
355Informations de copyright
Copyright: Mathurin Pierre Kowo et al.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
JAMA. 2013 Sep 4;310(9):974-6
pubmed: 24002285
Virol J. 2009 Sep 29;6:153
pubmed: 19788743
Lancet. 2016 Sep 10;388(10049):1089-1102
pubmed: 27427453
Rev Soc Bras Med Trop. 2013 Jan-Feb;46(1):24-9
pubmed: 23563821
J Glob Health. 2018 Dec;8(2):020407
pubmed: 30140433
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
BMC Public Health. 2018 Aug 15;18(1):1015
pubmed: 30111364
Eur J Intern Med. 2016 Oct;34:e21-e22
pubmed: 27189044
BMC Infect Dis. 2018 Feb 12;18(1):79
pubmed: 29433454
Pan Afr Med J. 2017 Jun 22;27(Suppl 3):17
pubmed: 29296152
BMC Infect Dis. 2016 Jun 06;16:249
pubmed: 27267370
Lancet. 1996 Sep 14;348(9029):696
pubmed: 8806283
J Urban Health. 2009 Jan;86(1):93-105
pubmed: 18622707
BMC Infect Dis. 2008 Mar 07;8:33
pubmed: 18328097
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
BMJ Open. 2017 Jun 30;7(6):e015298
pubmed: 28667212
Med J Aust. 2014 Mar 17;200(5):277-80
pubmed: 24641153
Vaccine. 2019 Aug 14;37(35):5059-5066
pubmed: 31285088
Am J Trop Med Hyg. 2009 Aug;81(2):240-7
pubmed: 19635877
J Infect Dev Ctries. 2009 Aug 30;3(7):539-47
pubmed: 19762972
Biomed Res Int. 2018 Sep 25;2018:3673289
pubmed: 30356352
J Med Microbiol. 2006 May;55(Pt 5):593-597
pubmed: 16585647